Pizer-BioNETech综合MRNA疫苗用于Covid-19和流感,未能证明在第三阶段试验中对B流感菌株的免疫反应有力。 Pfizer-BioNTech's combined mRNA vaccine for Covid-19 and influenza failed to demonstrate a robust immune response against the influenza B strain in Phase 3 trial.

Pizer-BioNTech综合MRNA疫苗用于Covid-19和流感,未能达到第三阶段试验的主要目标之一。 Pfizer-BioNTech's combined mRNA vaccine for Covid-19 and influenza failed to meet one of its primary goals in a Phase 3 trial. 虽然实验疫苗显示对甲型流感菌株的免疫反应很强,但对较不常见的乙型流感菌株的免疫反应也不相同。 While the experimental vaccine showed a robust immune response against the influenza A strain, it did not demonstrate a similar response against the less common influenza B strain. 混合疫苗对抗Covid-19的效果与Pfizer-BioNTEch的独立Covid-19疫苗Comernaty相似。 The combination vaccine's effectiveness against Covid-19 was comparable to that of Pfizer-BioNTech's standalone Covid-19 vaccine, Comirnaty. Pfizer和BioNTEch目前正在考虑进行修改,以改善疫苗对乙型流感菌株的性能,并将与卫生当局讨论下一步措施。 Pfizer and BioNTech are now considering modifications to improve the vaccine's performance against the influenza B strain and will discuss next steps with health authorities.